Medical Communications

Showing 15 posts of 6402 posts found.

New treatment for leukaemia nullifies cancer cells

October 13, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Boston, Cancer, Germany, Harvard, Mainz University, leukaemia

New research was able to demonstrate that a targeted drug-based inactivation of two chromatin regulators would interrupt the self-renewal of …
sunpharma

Sun Pharmaceuticals hit with recall of over 31 thousand bottles of anti-depressants

October 13, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, India, US, america, sun pharmaceutical

Sun Pharmaceuticals have been forced to recall 31,762 bottles of anti-depressants from the US market after the FDA issued a …

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …
paul_navarre

Nestlé appoints Paul Navarre as CEO of Nestlé Skin Health

October 12, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Nestle skin health, Paul Navarre, nestle

The announcement of Paul Navarre’s appointed as CEO of Nestlé Skin Health was announced on 11 October. He will take …
aaeaaqaaaaaaaaiyaaaajgqxy2rmmzrlltrhmzktndzhns05mza3lwmwmjliywjmzdu5zg

Sanofi appoint Alan Main to Executive Committee and Executive Vice President Consumer Healthcare

October 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Sanofi announced the appointment of Alan Main as Executive Vice President Consumer Healthcare effective October 1.Mr Main, who previously worked …
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
1280px-epi-pen_1

Mylan agrees $465m settlement over EpiPen misclassification

October 10, 2016 Business Services, Medical Communications, Sales and Marketing Heather Bresch, Mylan, Price hike, epipen

In the latest scandal in the EpiPen price hike saga, the US Department of Justice has made claims that the …

NICE recommends Forxiga in Triple Therapy for Diabetes

October 7, 2016 Medical Communications AstraZeneca, Forxiga, NHS, NICE, diabetes, type 2 diabetes

The news of NICE’s approval of the Forxiga comes in a busy week for AstraZeneca. They have sold three drugs, …
gsk_china_2_2_0_1

Cancer Research UK receives ‘success payment’ from GlaxoSmithKline

October 7, 2016 Medical Communications GSK, GlaxoSmithKline, University of Manchester, cancer research

CRT and the University of Manchester were rewarded financially for their collaboration developing molecules targeting cancer epigenetics. The agreement between …
top_ten_stories

Top Ten articles in the Pharma Industry this week

October 7, 2016 Medical Communications

The beginning of October has seen the failure of big drugs in clinical trials have a big knock-on effect for …
astrazeneca_building_white

AstraZeneca sells off third drug in five days

October 7, 2016 Medical Communications AstraZeneca, Cilag GmbH, Johnson & Johnson, Rhinocort Aqua

AstraZeneca have completed a third sell off in the course of one week by divesting rights to Rhinocort Aqua outside …

ICU Medical to acquire Pfizer’s global infusion therapy business in $1 billion deal

October 6, 2016 Medical Communications Hospira, ICU medical, Pfizer, acquisition, infusion

The $1 billion deal that will take place as ICU Medical Inc. take over Pfizer’s Hospira Infusion Systems will be …
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
The Gateway to Local Adoption Series

Latest content